Belfer Institute, sanofi-aventis collaborate to find anticancer drugs Dana-Farber Tumor Institute’s Belfer Institute of Applied Tumor Research and sanofi-aventis announced today they have entered right into a collaboration and license choice agreement to recognize and validate novel oncology targets for additional discovery and advancement by sanofi-aventis of novel therapeutics brokers directed to such targets and related biomarkers. Analysis at the Belfer Institute is targeted on understanding the essential mechanisms of cancers, finding and validating therapeutic targets and their medical context in advanced model systems, enabling development of medication response biomarkers and assisting the discovery and advancement of innovative cancer remedies. Belfer Institute and sanofi-aventis’ scientists will continue to work jointly with the purpose of discovering fresh anticancer drugs directed at specific individual populations any good .
An intensive concentrate on limiting our working costs will preserve considerable worth for our shareholders in the moderate to long term, specially the value produced from our partnership with Celtic Therapeutics for KIACTA. Our goal is by using our existing capital also to leverage our resources through partnerships as we move our items to commercialization. After we have applied today’s initiatives, new financings ought to be needless for the near future, he concluded.. Bellus Wellness reports net lack of $5.8M for second-one fourth vs. Net gain of $14.27M for earlier year Announcement of new initiatives to lessen burn rate BELLUS Wellness Inc. reported today its economic results for the next quarter ended June 30, 2010.